Use the collections feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Mizuki Onozawa, Koji Kawai, Takahiro Yamamoto, Shiro Hinotsu, Sadamu Tsukamoto, Kazunori Hattori, Naoto Miyanaga, Toru Shimazui, Hideyuki Akaza
BACKGROUND: Since the advent of cisplatin-based chemotherapy, the majority of metastatic testicular cancers can be cured by chemotherapy followed by retroperitoneal lymph node dissection (RPLND). However, postchemotherapy RPLND confers no therapeutic benefit if the residual mass contains no viable cells. Therefore, to determine which parameters predict a patient's likelihood of having only necrosis in the residual mass, we retrospectively analyzed clinical parameters of patients who underwent postchemotherapy RPLND...
July 2004: International Journal of Urology: Official Journal of the Japanese Urological Association
#22
REVIEW
Giuseppe Curigliano, Daniela Cardinale, Susan Dent, Carmen Criscitiello, Olexiy Aseyev, Daniel Lenihan, Carlo Maria Cipolla
Answer questions and earn CME/CNE Cancer and heart disease are the leading causes of morbidity and mortality in the industrialized world. Modern treatment strategies have led to an improvement in the chances of surviving a diagnosis of cancer; however, these gains can come at a cost. Patients may experience adverse cardiovascular events related to their cancer treatment or as a result of an exacerbation of underlying cardiovascular disease. With longer periods of survival, late effects of cancer treatment may become clinically evident years or decades after completion of therapy...
July 2016: CA: a Cancer Journal for Clinicians
#23
REVIEW
P Giannatempo, T Greco, L Mariani, N Nicolai, S Tana, E Farè, D Raggi, L Piva, M Catanzaro, D Biasoni, T Torelli, S Stagni, B Avuzzi, M Maffezzini, G Landoni, F De Braud, A M Gianni, G Sonpavde, R Salvioni, A Necchi
BACKGROUND: Outcomes of radiotherapy (RT) compared with chemotherapy (CT) remain poorly defined for clinical stage (CS) IIA and IIB seminoma. We aimed to evaluate the current role of the two treatment modalities in this setting of testicular seminoma. PATIENTS AND METHODS: A systematic review and meta-analysis (MA) was carried out to identify all evaluable studies. Search was limited to studies published after 1990 and included the Medline, Embase databases, and abstracts from ASCO (GU), ESMO, AUA, and ASTRO meetings up to April 2014...
April 2015: Annals of Oncology: Official Journal of the European Society for Medical Oncology
#24
REVIEW
Harold J Burstein, Christina Lacchetti, Holly Anderson, Thomas A Buchholz, Nancy E Davidson, Karen E Gelmon, Sharon H Giordano, Clifford A Hudis, Alexander J Solky, Vered Stearns, Eric P Winer, Jennifer J Griggs
PURPOSE: To update the ASCO adjuvant endocrine therapy guideline based on emerging data concerning the benefits and risks of ovarian suppression in addition to standard adjuvant therapy in premenopausal women with estrogen receptor-positive breast cancer. METHODS: ASCO convened an Update Panel and conducted a systematic review of randomized clinical trials investigating ovarian suppression. RESULTS: Two trials investigating the addition of ovarian suppression to tamoxifen did not show an overall clinical benefit for ovarian suppression...
May 10, 2016: Journal of Clinical Oncology
#25
REVIEW
Dario Baratti, Shigeki Kusamura, Filippo Pietrantonio, Marcello Guaglio, Monica Niger, Marcello Deraco
Peritoneal metastases (PM) from colorectal cancer (CRC) were traditionally associated with bad prognosis. Only recently, cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) has resulted in survival improvements. A systematic literature search between January 2010 and June 2015 was performed. Studies were selected and appraised according to predetermined criteria. Nineteen cohort studies, and thirteen comparative studies of CRS/HIPEC were included. The weighted median overall survival was 31...
April 2016: Critical Reviews in Oncology/hematology
#26
REVIEW
Ombretta Annibali, Francesco Sabatino, Flavio Mantelli, Odoardo Maria Olimpieri, Stefano Bonini, Giuseppe Avvisati
Over the last decades, we have witnessed an increase in the incidence of primary ocular adnexa lymphomas (POALs) probably because advances in imaging techniques have enabled precise biopsies of the tumors. The ocular tissue biopsy, before the initiation of the appropriate treatment, is mandatory and necessary for a correct diagnosis of POALs by the use of immunophenotyping and a correct molecular classification. Only in a minority of cases the ocular adnexa are secondarily affected by a systemic disease. Among the POALs, the most common is the primary extra nodal lymphoma of MALT-type (POAML)...
April 2016: Critical Reviews in Oncology/hematology
#27
REVIEW
S Vincent Rajkumar, Shaji Kumar
The diagnosis and treatment of multiple myeloma has changed dramatically in the past decade. The disease definition has been updated to include highly specific biomarkers in addition to established markers of end-organ damage. The staging system has been revised to combine both measures of tumor burden and disease biology. Advances in therapy have resulted in a marked improvement in overall survival. New drugs introduced in the past few years include carfilzomib, pomalidomide, panobinostat, ixazomib, elotuzumab, and daratumumab...
January 2016: Mayo Clinic Proceedings
#28
JOURNAL ARTICLE
John G Touzios, James M Kiely, Susan C Pitt, William S Rilling, Edward J Quebbeman, Stuart D Wilson, Henry A Pitt
OBJECTIVE: The aim of this study was to determine whether aggressive management of neuroendocrine hepatic metastases improves survival. SUMMARY BACKGROUND DATA: Survival in patients with carcinoid and pancreatic neuroendocrine tumors is significantly better than adenocarcinomas arising from the same organs. However, survival and quality of life are diminished in patients with neuroendocrine hepatic metastases. In recent years, aggressive treatment of hepatic neuroendocrine tumors has been shown to relieve symptoms...
May 2005: Annals of Surgery
#29
JOURNAL ARTICLE
J Philip Boudreaux, Bradley Putty, Daniel J Frey, Eugene Woltering, Lowell Anthony, Ivonne Daly, Thiagarajan Ramcharan, Jorge Lopera, Wilfrido Castaneda
OBJECTIVE: To evaluate clinical outcomes in a large group of advanced-stage carcinoid patients (stage IV) following multimodal surgical therapy. SUMMARY BACKGROUND DATA: Patients with advanced-stage carcinoid have traditionally experienced poor 5-year survival (18%-30%). Few recent series have evaluated a large number of patients treated with aggressive surgical rescue therapy. METHODS: This single-center retrospective review analyzes the records of 82 consecutive carcinoid patients treated by the same 2 surgeons, from August 1998 through August 2004 with a 3- to 72-month follow-up...
June 2005: Annals of Surgery
#30
REVIEW
Lois B Travis, Clair Beard, James M Allan, Alv A Dahl, Darren R Feldman, Jan Oldenburg, Gedske Daugaard, Jennifer L Kelly, M Eileen Dolan, Robyn Hannigan, Louis S Constine, Kevin C Oeffinger, Paul Okunieff, Greg Armstrong, David Wiljer, Robert C Miller, Jourik A Gietema, Flora E van Leeuwen, Jacqueline P Williams, Craig R Nichols, Lawrence H Einhorn, Sophie D Fossa
Testicular cancer represents the most curable solid tumor, with a 10-year survival rate of more than 95%. Given the young average age at diagnosis, it is estimated that effective treatment approaches, in particular, platinum-based chemotherapy, have resulted in an average gain of several decades of life. This success, however, is offset by the emergence of considerable long-term morbidity, including second malignant neoplasms, cardiovascular disease, neurotoxicity, nephrotoxicity, pulmonary toxicity, hypogonadism, decreased fertility, and psychosocial problems...
August 4, 2010: Journal of the National Cancer Institute
#31
MULTICENTER STUDY
Karim Fizazi, Rémi Delva, Armelle Caty, Christine Chevreau, Pierre Kerbrat, Frederic Rolland, Frank Priou, Lionnel Geoffrois, Olivier Rixe, Philippe Beuzeboc, Jean-Pierre Malhaire, Stephane Culine, Marie-Stephanie Aubelle, Agnes Laplanche
BACKGROUND: Whether patients with good prognosis and intermediate/poor prognosis advanced seminoma should be treated differently has not been defined. OBJECTIVE: To assess a risk-adapted chemotherapy regimen in patients with advanced seminoma. DESIGN, SETTING, AND PARTICIPANTS: A total of 132 patients were included in this prospective study. Patients with a good prognosis according to the International Germ Cell Cancer Collaboration Group (IGGCCG) were treated with four cycles of cisplatin-etoposide (EP)...
February 2014: European Urology
#32
REVIEW
Shellese A Cannonier, Julie A Sterling
Despite significant progress in cancer treatments, tumor induced bone disease continues to cause significant morbidities. While tumors show distinct mutations and clinical characteristics, they behave similarly once they establish in bone. Tumors can metastasize to bone from distant sites (breast, prostate, lung), directly invade into bone (head and neck) or originate from the bone (melanoma, chondrosarcoma) where they cause pain, fractures, hypercalcemia, and ultimately, poor prognoses and outcomes. Tumors in bone secrete factors (interleukins and parathyroid hormone-related protein) that induce RANKL expression from osteoblasts, causing an increase in osteoclast mediated bone resorption...
August 26, 2015: Cancers
#33
REVIEW
Paula Cramer, Petra Langerbeins, Barbara Eichhorst, Michael Hallek
The management of patients with CLL is undergoing significant changes; during the last decade, the outcome of first-line therapies has been markedly improved with the addition of anti-CD20 antibodies to chemotherapy. Today, chemoimmunotherapy for physically fit patients ≤ 65 years should consist of fludarabine, cyclophosphamide, and rituximab (FCR). The combination of bendamustine and rituximab (BR) should be considered in physically fit patients > 65 years and in patients with a higher risk of infections...
January 2016: European Journal of Haematology
#34
REVIEW
Marc B Grodsky, Shafik M Sidani
Radiation therapy is a widely utilized treatment modality for pelvic malignancies, including prostate cancer, rectal cancer, and cervical cancer. Given its fixed position in the pelvis, the rectum is at a high risk for injury secondary to ionizing radiation. Despite advances made in radiation science, up to 75% of the patients will suffer from acute radiation proctitis and up to 20% may experience chronic symptoms. Symptoms can be variable and include diarrhea, bleeding, incontinence, and fistulization. A multitude of treatment options exist...
June 2015: Clinics in Colon and Rectal Surgery
#35
REVIEW
Philippe D Violette, Thomas Agoritsas, Paul Alexander, Jarno Riikonen, Henrikki Santti, Arnav Agarwal, Neera Bhatnagar, Philipp Dahm, Victor Montori, Gordon H Guyatt, Kari A O Tikkinen
Patients who are diagnosed with localized prostate cancer need to make critical treatment decisions that are sensitive to their values and preferences. The role of decision aids in facilitating these decisions is unknown. The authors conducted a systematic review of randomized trials of decision aids for localized prostate cancer. Teams of 2 reviewers independently identified, selected, and abstracted data from 14 eligible trials (n = 3377 men), of which 10 were conducted in North America. Of these, 11 trials compared decision aids with usual care, and 3 trials compared decision aids with other decision aids...
May 2015: CA: a Cancer Journal for Clinicians
#36
REVIEW
Gina Chia-Yi Chu, Leland W K Chung
Cancer metastasis is highly inefficient and complex. Common features of metastatic cancer cells have been observed using cancer cell lines and genetically reconstituted mouse and human tumor xenograft models. These include cancer cell interaction with the tumor microenvironment and the ability of cancer cells to sense extracellular stimuli and adapt to adverse growth conditions. This review summarizes the coordinated response of cancer cells to soluble growth factors, such as RANKL, by a unique feed forward mechanism employing coordinated upregulation of RANKL and c-Met with downregulation of androgen receptor...
September 2014: Cancer Metastasis Reviews
#37
REVIEW
Douglas Hanahan
Some 40 years ago a metaphor was posed that cancer was such an insidious adversary that a declaration of war on the disease was justified. Although this statement was a useful inspiration for enlistment of resources, despite extraordinary progress in our understanding of disease pathogenesis, in most cases and for most forms of cancer this war has not been won. A second metaphor was about magic bullets--targeted therapies based on knowledge of mechanisms that were envisaged to strike with devastating consequences for the disease...
February 8, 2014: Lancet
#38
REVIEW
Christopher L Wolfgang, Joseph M Herman, Daniel A Laheru, Alison P Klein, Michael A Erdek, Elliot K Fishman, Ralph H Hruban
Pancreatic cancer is currently one of the deadliest of the solid malignancies. However, surgery to resect neoplasms of the pancreas is safer and less invasive than ever, novel drug combinations have been shown to improve survival, advances in radiation therapy have resulted in less toxicity, and enormous strides have been made in the understanding of the fundamental genetics of pancreatic cancer. These advances provide hope but they also increase the complexity of caring for patients. It is clear that multidisciplinary care that provides comprehensive and coordinated evaluation and treatment is the most effective way to manage patients with pancreatic cancer...
September 2013: CA: a Cancer Journal for Clinicians
#39
REVIEW
H J Schmoll, R Souchon, S Krege, P Albers, J Beyer, C Kollmannsberger, S D Fossa, N E Skakkebaek, R de Wit, K Fizazi, J P Droz, G Pizzocaro, G Daugaard, P H M de Mulder, A Horwich, T Oliver, R Huddart, G Rosti, L Paz Ares, O Pont, J T Hartmann, N Aass, F Algaba, M Bamberg, I Bodrogi, C Bokemeyer, J Classen, S Clemm, S Culine, M de Wit, H G Derigs, K P Dieckmann, M Flasshove, X Garcia del Muro, A Gerl, J R Germa-Lluch, M Hartmann, A Heidenreich, W Hoeltl, J Joffe, W Jones, G Kaiser, O Klepp, S Kliesch, L Kisbenedek, K U Koehrmann, M Kuczyk, M P Laguna, O Leiva, V Loy, M D Mason, G M Mead, R P Mueller, N Nicolai, G O N Oosterhof, T Pottek, O Rick, H Schmidberger, F Sedlmayer, W Siegert, U Studer, S Tjulandin, H von der Maase, P Walz, S Weinknecht, L Weissbach, E Winter, C Wittekind
Germ cell tumour is the most frequent malignant tumour type in young men with a 100% rise in the incidence every 20 years. Despite this, the high sensitivity of germ cell tumours to platinum-based chemotherapy, together with radiation and surgical measures, leads to the high cure rate of > or = 99% in early stages and 90%, 75-80% and 50% in advanced disease with 'good', 'intermediate' and 'poor' prognostic criteria (IGCCCG classification), respectively. The high cure rate in patients with limited metastatic disease allows the reduction of overall treatment load, and therefore less acute and long-term toxicity, e...
September 2004: Annals of Oncology: Official Journal of the European Society for Medical Oncology
1
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
